Unfortunately, nearly half of CRC cases harbor KRAS mutations, which are negative predictive markers for antiEGFR therapy5 and common drivers of innate and acquired resistance6 (Supplementary Fig. 1a). This evidence concerns the gene KRAS and colorectal carcinoma.